Plain-English translation of NCT06578533 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called (Lokelma) to help manage high potassium levels in people with chronic kidney disease. Many patients with kidney disease need to take medications that protect the heart and kidneys, but these drugs can dangerously raise potassium levels, which can cause irregular heartbeats. This study compares whether adding this medication allows patients to stay safely on their heart-protective drugs.
High potassium is a serious problem for people with kidney disease who take heart-protective medications—so serious that many patients have to reduce or stop those protective drugs, which means they lose important health benefits. This trial exists to see if the medication can help patients keep taking their full doses of heart-protective drugs while safely managing potassium levels.
You likely qualify if…
You likely don't qualify if…
You would visit the study center 7 times over about 3 months (90 days). At your first visit, blood tests would confirm your potassium level qualifies you. Then you would be randomly assigned to one of two groups: either continue your current heart-protective medications while adding the new oral medication (which you mix with water and drink), or have your heart-protective medications reduced or stopped as is standard practice. Throughout the study, you would have regular blood tests to monitor your potassium levels and heart health.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Spain